{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:28:39Z","timestamp":1795141719821,"version":"4.10.3"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neuropharm.2024.110020","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T19:17:22Z","timestamp":1717010242000},"page":"110020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Microglia and TREM2"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9331","authenticated-orcid":false,"given":"Jennifer","family":"Pocock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Vasilopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Cosker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110020_bib1","unstructured":"https:\/\/www.alzforum.org\/news\/conference-coverage\/all-roads-lead-trem2-gearing-target-receptor, https:\/\/www.alzforum.org\/therapeutics\/al002."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110020_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41593-020-0650-6","article-title":"Alzheimer\u2019s-associated PLC\u03b32 is a signalling node required for both TREM2 function and the inflammatory response in human microglia","volume":"23","author":"Andreone","year":"2020","journal-title":"Nat. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110020_bib3","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","article-title":"Depletion of microglia and inhibition of exosome synthesis halt tau propagation","volume":"18","author":"Asai","year":"2015","journal-title":"Nat. Neurosci."},{"issue":"43","key":"10.1016\/j.neuropharm.2024.110020_bib4","doi-asserted-by":"crossref","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","article-title":"Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2)","volume":"290","author":"Atagi","year":"2015","journal-title":"J.Biol.Chem."},{"issue":"s1","key":"10.1016\/j.neuropharm.2024.110020_bib5","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.3233\/JAD-221070","article-title":"Untangling the role of TREM2 in conjugation with microglia in neuronal dysfunction: a hypothesis on a novel pathway in the pathophysiology of alzheimer's disease","volume":"94","author":"Basha","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2024.110020_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.635104","article-title":"Exosomes: innocent bystanders or critical culprits in neurodegenerative diseases","volume":"9","author":"Beatriz","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110020_bib7","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114486119","article-title":"Soluble TREM2 inhibits secondary nucleation of A\u03b2 fibrillization and enhances cellular uptake of fibrillar A\u03b2","volume":"119","author":"Belsare","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:CEMN.0000012721.08168.ee","article-title":"Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects","volume":"24","author":"Bianchin","year":"2004","journal-title":"Cell. Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110020_bib11","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/glia.24252","article-title":"Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cells","volume":"70","author":"Boudesco","year":"2022","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib12","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.stemcr.2018.03.003","article-title":"Functional studies of missense TREM2 mutations in human stem cell-derived microglia","volume":"10","author":"Brownjohn","year":"2018","journal-title":"Stem Cell Rep."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110020_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41583-018-0057-5","article-title":"Microglial signatures and their role in health and disease","volume":"19","author":"Butovsky","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/jamaneurol.2013.6237","article-title":"TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis","volume":"71","author":"Cady","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00251-011-0562-4","article-title":"Specific lipid recognition is a general feature of CD300 and TREM molecules","volume":"64","author":"Cannon","year":"2012","journal-title":"Immunogenetics"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110020_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00401-015-1388-1","article-title":"TREM2 regulates microglial cell activation in response to demyelination in vivo","volume":"129","author":"Cantoni","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib17","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1038\/s41467-023-42819-w","article-title":"INPP5D regulates inflammasome activation in human microglia","volume":"14","author":"Chou","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110020_bib18","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1002\/humu.20836","article-title":"Mutations in TREM2 lead to pure early-onset dementia without bone cysts","volume":"29","author":"Chouery","year":"2008","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00401-020-02193-z","article-title":"TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis","volume":"140","author":"Cignarella","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-021-00473-0","article-title":"Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer's disease","volume":"16","author":"Claes","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2024.110020_bib21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","article-title":"The biology of TREM receptors","volume":"23","author":"Colonna","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91207-1","article-title":"Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome","volume":"11","author":"Cosker","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/00207454.2020.1750388","article-title":"Assessment of TREM2 rs75932628 variant's association with Parkinson's disease in a Greek population and Meta-analysis of current data","volume":"131","author":"Dardiotis","year":"2021","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-023-00343-3","article-title":"Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis","volume":"12","author":"De Dios","year":"2023","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-019-0319-3","article-title":"TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers","volume":"14","author":"Del-Aguila","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"505","key":"10.1016\/j.neuropharm.2024.110020_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau2291","article-title":"The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk","volume":"11","author":"Deming","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110020_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017742118","article-title":"Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer's disease","volume":"118","author":"Ellwanger","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"507","key":"10.1016\/j.neuropharm.2024.110020_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav6221","article-title":"Alzheimer's Disease Neuroimaging I. (2019). Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease","volume":"11","author":"Ewers","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-01980-5","article-title":"Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer's disease models","volume":"18","author":"Fassler","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2024.110020_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2017.09.034","article-title":"ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157","volume":"660","author":"Feuerbach","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00401-023-02568-y","article-title":"Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation","volume":"145","author":"Filipello","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib32","doi-asserted-by":"crossref","first-page":"546.e9","DOI":"10.1016\/j.neurobiolaging.2014.08.001","article-title":"TREM2 analysis and increased risk of Alzheimer's disease","volume":"36","author":"Finelli","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13108","article-title":"TREM2-induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer's neuropathology","volume":"33","author":"Fracassi","year":"2023","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12974-023-02895-7","article-title":"miR155, TREM2, INPP5D: disease stage and cell type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer's amyloidopathy","volume":"20","author":"Gandy","year":"2023","journal-title":"J. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110020_bib35","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.celrep.2018.07.094","article-title":"Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis","volume":"24","author":"Garcia-Reitboeck","year":"2018","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110020_bib36","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.4103\/1673-5374.371360","article-title":"TREM2 as an evolving therapeutic target in Alzheimer's disease","volume":"18","author":"George","year":"2023","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.neuropharm.2024.110020_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12974-016-0479-9","article-title":"Functional involvement of gamma-secretase in signalling of the triggering receptor expressed on myeloid cells-2 (TREM2)","volume":"13","author":"Glebov","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's Disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110020_bib39","doi-asserted-by":"crossref","first-page":"12164","DOI":"10.1096\/fj.201900992R","article-title":"TREM2 deficiency aggravates \u03b1-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models","volume":"33","author":"Guo","year":"2019","journal-title":"Faseb. J."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.stemcr.2017.05.017","article-title":"A highly efficient human pluripotent stem cell microglia model displays a neuronal-Co-culture-Specific expression profile and inflammatory response","volume":"8","author":"Haenseler","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.neuropharm.2024.110020_bib41","first-page":"1","article-title":"Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia","volume":"232","author":"Hakola","year":"1972","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13195-020-00709-z","article-title":"TREM2 Alzheimer's variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages","volume":"12","author":"Hall-Roberts","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110020_bib43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.freeradbiomed.2006.12.003","article-title":"Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid beta and interferon-gamma-induced microglial activation","volume":"42","author":"Hashioka","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","article-title":"Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease","volume":"11","author":"Heslegrave","year":"2016","journal-title":"Mol. Neurodegener."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110020_bib45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/glia.23953","article-title":"A reporter cell system for the triggering receptor expressed on myeloid cells 2 reveals differential effects of disease-associated variants on receptor signaling and activation by antibodies against the stalk region","volume":"69","author":"Ibach","year":"2021","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib46","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220654","article-title":"Chronic TREM2 activation exacerbates A\u03b2-associated tau seeding and spreading","volume":"220","author":"Jain","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib47","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73021","article-title":"TREM2 regulates purinergic receptor-mediated calcium signaling and motility in human iPSC-derived microglia","volume":"11","author":"Jairaman","year":"2022","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110020_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20142322","article-title":"TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models","volume":"212","author":"Jay","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbi.2023.01.013","article-title":"Profiling TREM2 expression in amyotrophic lateral sclerosis","volume":"109","author":"Jeric\u00f3","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"21","key":"10.1016\/j.neuropharm.2024.110020_bib50","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","article-title":"Coding variants in TREM2 increase risk for Alzheimer's disease","volume":"23","author":"Jin","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110020_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13623","article-title":"Amyloid-\u03b2 activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Syk-AMPK pathway","volume":"21","author":"Jung","year":"2022","journal-title":"Aging Cell"},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110020_bib53","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting development of alzheimer's disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110020_bib55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/JLB.2HI0720-463RR","article-title":"Novel TREM2 splicing isoform that lacks the V-set immunoglobulin domain is abundant in the human brain","volume":"110","author":"Kiianitsa","year":"2021","journal-title":"J. Leukoc. Biol."},{"issue":"13","key":"10.1016\/j.neuropharm.2024.110020_bib56","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.15252\/embj.201796516","article-title":"The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism","volume":"36","author":"Kleinberger","year":"2017","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110020_bib57","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1212\/01.WNL.0000160304.00003.CA","article-title":"The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2","volume":"64","author":"Kl\u00fcnemann","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2024.110020_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.651973","article-title":"The emerging role of the interplay among astrocytes, microglia, and neurons in the Hippocampus in health and disease","volume":"13","author":"Lana","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110020_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fimmu.2020.00493","article-title":"Metabolic reprograming of microglia in the regulation of the innate inflammatory response","volume":"11","author":"Lauro","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110020_bib60","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","article-title":"TREM2 function impedes tau seeding in neuritic plaques","volume":"22","author":"Leyns","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14630","article-title":"TREM2 gene induces differentiation of induced pluripotent stem cells into dopaminergic neurons and promotes neuronal repair via TGF-\u03b2 activation in 6-OHDA-lesioned mouse model of Parkinson's disease","volume":"30","author":"Liang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2024.110020_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101719","article-title":"Can the emerging field of immunometabolism provide insights into neuroinflammation?","volume":"184","author":"Lynch","year":"2020","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib64","doi-asserted-by":"crossref","first-page":"fcab009","DOI":"10.1093\/braincomms\/fcab009","article-title":"The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles","volume":"3","author":"Mallach","year":"2021","journal-title":"Brain Commun"},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110020_bib65","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3390\/cells10112866","article-title":"Differential stimulation of pluripotent stem cell-derived human microglia leads to exosomal proteomic changes affecting neurons","volume":"10","author":"Mallach","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-018-0297-x","article-title":"Development and validation of a simplified method to generate human microglia from pluripotent stem cells","volume":"13","author":"McQuade","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2024.110020_bib68","series-title":"Healthy Adult Volunteers 1148th Annual Meeting of the American Neurological Association, September","article-title":"A Phase 1, First-in-Human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist","volume":"vols. 9\u201312","author":"Meier","year":"2023"},{"key":"10.1016\/j.neuropharm.2024.110020_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1291115","article-title":"Leveraging iPSC technology to assess neuro-immune interactions in neurological and psychiatric disorders","volume":"14","author":"Michalski","year":"2023","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13073-023-01160-z","article-title":"TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation","volume":"15","author":"Moutinho","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.plefa.2018.07.006","article-title":"Role of metabolic programming in the modulation of microglia phagocytosis by lipids","volume":"135","author":"Nadjar","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.neuropharm.2024.110020_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2006.11.032","article-title":"Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis","volume":"184","author":"Neumann","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/alz.045839","article-title":"Targeting SHIP1 for therapeutic intervention in Alzheimer's disease","volume":"16","author":"Obst","year":"2020","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96144-7","article-title":"PLC\u03b32 regulates TREM2 signalling and integrin-mediated adhesion and migration of human iPSC-derived macrophages","volume":"11","author":"Obst","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110020_bib76","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.56.11.1552","article-title":"CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts","volume":"56","author":"Paloneva","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib77","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20030027","article-title":"DAP12\/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features","volume":"198","author":"Paloneva","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib78","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tra.12264","article-title":"Disease\u2010associated mutations of TREM2 alter the processing of N\u2010linked oligosaccharides in the golgi apparatus","volume":"16","author":"Park","year":"2015","journal-title":"Traffic"},{"key":"10.1016\/j.neuropharm.2024.110020_bib79","first-page":"1654","article-title":"TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1","volume":"45","author":"Peng","year":"2010","journal-title":"Sci. Signal."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib80","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12031-019-01424-7","article-title":"Analysis of cerebrospinal fluid soluble TREM2 and polymorphisms in sporadic Parkinson's disease in a Chinese population","volume":"70","author":"Peng","year":"2020","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib81","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/glia.24485","article-title":"iPSC-derived microglia carrying the TREM2 R47H\/+ mutation are proinflammatory and promote synapse loss","volume":"72","author":"Penney","year":"2024","journal-title":"Glia"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2024.110020_bib82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/21678421.2018.1451894","article-title":"TREM2 variants in neurodegenerative disorders in the Polish population. Homozygosity and compound heterozygosity in FTD patients","volume":"19","author":"Peplonska","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib83","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1096\/fj.201902447R","article-title":"A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia","volume":"34","author":"Piers","year":"2020","journal-title":"Faseb. J."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110020_bib84","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41583-018-0030-3","article-title":"Modelling microglial function with induced pluripotent stem cells: an update","volume":"19","author":"Pocock","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib85","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/glia.24318","article-title":"Alzheimer's disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss","volume":"71","author":"Popescu","year":"2023","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110020_bib86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/10738584211040786","article-title":"Microglial TREM2 at the intersection of brain aging and alzheimer's disease","volume":"29","author":"Qu","year":"2023","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2024.110020_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.617860","article-title":"Alzheimer's risk gene TREM2 determines functional properties of new type of human iPSC-derived microglia","volume":"11","author":"Reich","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib88","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2019.07.007","article-title":"TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort","volume":"35","author":"Rikos","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110020_bib89","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.15252\/emmm.201707672","article-title":"An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function","volume":"9","author":"Schlepckow","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib90","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911227","article-title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region","volume":"12","author":"Schlepckow","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib91","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3233\/JAD-215602","article-title":"An alternatively spliced TREM2 isoform lacking the ligand binding domain is expressed in human brain","volume":"87","author":"Shaw","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110020_bib92","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1096\/fj.201900527R","article-title":"Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP\/PS1 mice","volume":"33","author":"Sheng","year":"2019","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib93","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12974-021-02340-7","article-title":"Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology","volume":"18","author":"Sheng","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib94","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1038\/s41598-019-43535-6","article-title":"Aminophospholipids are signal-transducing TREM2 ligands on apoptotic cells","volume":"9","author":"Shirotani","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib95","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13543776.2021.1883587","article-title":"Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates","volume":"31","author":"Singh","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2024.110020_bib97","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2024.110020_bib98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fncel.2018.00323","article-title":"Bidirectional microglia-neuron communication in health and disease","volume":"12","author":"Szepesi","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110020_bib99","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.str.2021.06.010","article-title":"Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain","volume":"29","author":"Szykowska","year":"2021","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.immuni.2023.12.002","article-title":"Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development","volume":"57","author":"Tagliatti","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2024.110020_bib101","first-page":"647","article-title":"Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med","volume":"201","author":"Takahashi","year":"2005"},{"key":"10.1016\/j.neuropharm.2024.110020_bib103","unstructured":"Tchessalova D, Larson KC, Gergits FW, Renoux A, Figley M, Mirescu C. VGL101 rescues CSF1R dysfunction in human microglia and macrophages: evaluation of in vitro TREM2 agonism in models of a CSF1R-dependent leukodystrophy. The 2022 Alzheimer's Association International Conference (AAIC) - P2-05 Basic Science and Pathogenesis: Molecular and Cell Biology, Poster 090."},{"key":"10.1016\/j.neuropharm.2024.110020_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-023-00674-9","article-title":"Microglial function, INPP5D\/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer's disease","volume":"18","author":"Terzioglu","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110020_bib105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.15252\/emmm.201707673","article-title":"TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant","volume":"9","author":"Thornton","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110020_bib106","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","article-title":"TREM2 maintains microglial metabolic fitness in alzheimer's disease","volume":"170","author":"Ulland","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110020_bib107","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110020_bib108","first-page":"416","article-title":"A TREM2-activating antibody with a blood\u2013brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110020_bib109","article-title":"Amelioration of signalling deficits underlying metabolic shortfall in TREM2R47H human iPSC-derived microglia","author":"Vasilopoulou","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.neuropharm.2024.110020_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100631","article-title":"Wild-type sTREM2 blocks A\u03b2 aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases A\u03b2 aggregation","volume":"296","author":"Vilalta","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib112","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","article-title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110020_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21887","article-title":"Amyloid \u03b2 induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase- and mitochondria-dependent ROS production","volume":"31","author":"Wang","year":"2017","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110020_bib114","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110020_bib115","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/glia.24335","article-title":"TREM2-dependent microglial function is essential for remyelination and subsequent neuroprotection","volume":"71","author":"Wang","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2024.110020_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110020_bib117","doi-asserted-by":"crossref","first-page":"33027","DOI":"10.1074\/jbc.M113.517540","article-title":"Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage","volume":"288","author":"Wunderlich","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-018-0280-6","article-title":"The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans","volume":"13","author":"Xiang","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41593-021-00975-6","article-title":"TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration","volume":"25","author":"Xie","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib121","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12974-020-01878-2","article-title":"TREM2 ectodomain and its soluble form in Alzheimer's disease","volume":"17","author":"Yang","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110020_bib122","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","article-title":"TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia","volume":"91","author":"Yeh","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110020_bib123","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212479","article-title":"Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia","author":"Zhao","year":"2022","journal-title":"J. Exp. Med."},{"issue":"661","key":"10.1016\/j.neuropharm.2024.110020_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq0095","article-title":"A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib125","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41467-019-09118-9","article-title":"Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model","volume":"10","author":"Zhong","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110020_bib126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13024-022-00562-8","article-title":"Trem2 deletion enhances tau dispersion and pathology through microglia exosomes","volume":"17","author":"Zhu","year":"2022","journal-title":"Mol. Neurodegener."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T19:38:06Z","timestamp":1728243486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":116,"alternative-id":["S0028390824001898"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110020","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microglia and TREM2","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110020"}}